REG-Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026
Key Highlights
- ➤Alvotech (ALVO) will report nine-month and Q3 2026 results November 11
- ➤Alvotech will host a live earnings Q&A webcast November 12 at 08:00 ET
- ➤Five Alvotech biosimilars are approved and marketed across multiple global markets
REYKJAVIK, ICELAND (October 28, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will release its financial results for the nine months and third quarter ended September 30, 2026 on Wednesday, November 11, 2026, after the U.S. market close.
The Company will also host a webcast with a live Q&A on Thursday, November 12, 2026, at 08:00 ET (13:00 GMT, 14:00 CET). * To listen to the earnings call, please register here: 9M 2026 webcast * To participate in the Q&A, please register here: Q&A registration Slides and other materials will be made available on alvotech.com/financials before the earnings call.
Get started
Create a free account to read the full story.